Literature DB >> 30933266

Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.

Silke Polsfuss1, Sabine Hofmann-Thiel2,3, Matthias Merker4,5, David Krieger6, Stefan Niemann4,5, Holger Rüssmann1, Nicolas Schönfeld6, Harald Hoffmann2,3, Katharina Kranzer7,8.   

Abstract

Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  XDR-tuberculosis; bedaquiline resistance; delamanid resistance

Year:  2019        PMID： 30933266     DOI： 10.1093/cid/ciz074

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  18 in total

Review 1.  The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.

Authors:  Ahmed A Abulfathi; Peter R Donald; Kim Adams; Elin M Svensson; Andreas H Diacon; Helmuth Reuter
Journal:  Br J Clin Pharmacol       Date:  2020-06-21       Impact factor: 4.335

2.  Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.

Authors:  S Battaglia; A Spitaleri; A M Cabibbe; C J Meehan; C Utpatel; N Ismail; S Tahseen; A Skrahina; N Alikhanova; S M Mostofa Kamal; A Barbova; S Niemann; R Groenheit; A S Dean; M Zignol; L Rigouts; D M Cirillo
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

3.  Artemisia annua and Artemisia afra extracts exhibit strong bactericidal activity against Mycobacterium tuberculosis.

Authors:  Maria Carla Martini; Tianbi Zhang; John T Williams; Robert B Abramovitch; Pamela J Weathers; Scarlet S Shell
Journal:  J Ethnopharmacol       Date:  2020-07-27       Impact factor: 4.360

4.  Design of Multidrug-Resistant Tuberculosis Treatment Regimens Based on DNA Sequencing.

Authors:  Hans-Peter Grobbel; Matthias Merker; Niklas Köhler; Sönke Andres; Harald Hoffmann; Jan Heyckendorf; Maja Reimann; Ivan Barilar; Viola Dreyer; Doris Hillemann; Barbara Kalsdorf; Thomas A Kohl; Patricia Sanchez Carballo; Dagmar Schaub; Katharina Todt; Christian Utpatel; Florian P Maurer; Christoph Lange; Stefan Niemann
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

5.  Dynamics of within-host Mycobacterium tuberculosis diversity and heteroresistance during treatment.

Authors:  Camus Nimmo; Kayleen Brien; James Millard; Alison D Grant; Nesri Padayatchi; Alexander S Pym; Max O'Donnell; Richard Goldstein; Judith Breuer; François Balloux
Journal:  EBioMedicine       Date:  2020-04-28       Impact factor: 8.143

6.  A landscape of genomic alterations at the root of a near-untreatable tuberculosis epidemic.

Authors:  Marisa Klopper; Tim Hermanus Heupink; Grant Hill-Cawthorne; Elizabeth Maria Streicher; Anzaan Dippenaar; Margaretha de Vos; Abdallah Musa Abdallah; Jason Limberis; Matthias Merker; Scott Burns; Stefan Niemann; Keertan Dheda; James Posey; Arnab Pain; Robin Mark Warren
Journal:  BMC Med       Date:  2020-02-04       Impact factor: 8.775

7.  MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era.

Authors:  Patrick Beckert; Elisabeth Sanchez-Padilla; Matthias Merker; Viola Dreyer; Thomas A Kohl; Christian Utpatel; Claudio U Köser; Ivan Barilar; Nazir Ismail; Shaheed Vally Omar; Marisa Klopper; Robin M Warren; Harald Hoffmann; Gugu Maphalala; Elisa Ardizzoni; Bouke C de Jong; Bernhard Kerschberger; Birgit Schramm; Sönke Andres; Katharina Kranzer; Florian P Maurer; Maryline Bonnet; Stefan Niemann
Journal:  Genome Med       Date:  2020-11-25       Impact factor: 11.117

8.  Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics.

Authors:  Kirsten E Knoll; Zander Lindeque; Adetomiwa A Adeniji; Carel B Oosthuizen; Namrita Lall; Du Toit Loots
Journal:  Microorganisms       Date:  2021-05-28

Review 9.  Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid.

Authors:  Luisa Maria Nieto Ramirez; Karina Quintero Vargas; Gustavo Diaz
Journal:  Antibiotics (Basel)       Date:  2020-03-23

10.  Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients.

Authors:  Martina L Reichmuth; Rico Hömke; Kathrin Zürcher; Peter Sander; Anchalee Avihingsanon; Jimena Collantes; Chloé Loiseau; Sonia Borrell; Miriam Reinhard; Robert J Wilkinson; Marcel Yotebieng; Lukas Fenner; Erik C Böttger; Sebastien Gagneux; Matthias Egger; Peter M Keller
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.